Edition:
United Kingdom

Tecan Group AG (TECN.S)

TECN.S on Swiss Exchange

224.40CHF
19 Oct 2018
Change (% chg)

CHF-0.80 (-0.36%)
Prev Close
CHF225.20
Open
CHF224.40
Day's High
CHF226.20
Day's Low
CHF222.00
Volume
19,817
Avg. Vol
25,978
52-wk High
CHF256.00
52-wk Low
CHF178.60

Summary

Name Age Since Current Position

Lukas Braunschweiler

61 2018 Non-Executive Chairman of the Board

David Martyr

61 2012 Chief Executive Officer, Member of the Management Board

Heinrich Fischer

68 2007 Non-Executive Vice Chairman of the Board

Rudolf Eugster

53 2002 Chief Financial Officer, Member of the Management Board

Ulrich Kanter

55 2014 Executive Vice President, Head of the Division Development and Operations, Member of the Management Board

Andreas Wilhelm

49 2012 Executive Vice President General Counsel and Secretary of the Board of Directors, Member of the Management Board

Markus Schmid

50 2011 Executive Vice President, Head of Corporate Human Resources & Internal Communications, Member of the Management Board

Klaus Lun

46 2017 Executive Vice President, Head of the Life Sciences Business Division, Member of the Management Board

Erik Norstrom

44 2017 Executive Vice President, Head of Corporate Development, Member of the Management Board

Achim von Leoprechting

50 2013 Executive Vice President, Head of the Partnering Business Division, Member of the Management Board

Oliver Fetzer

54 2011 Non-Executive Director

Lars Holmqvist

59 2015 Non-Executive Director

Karen Huebscher

55 2012 Non-Executive Director

Christa Kreuzburg

59 2013 Non-Executive Director

Daniel Marshak

61 2018 Non-Executive Director

Martin Braendle

2017 Vice President, Communications & Investor Relations

Biographies

Name Description

Lukas Braunschweiler

Dr. Lukas Braunschweiler has been Non-Executive Chairman of the Board of Tecan Group Ltd. since 2018. He is Chairman of the Nomination and Governance Committee at the Company. He served as Non-Executive Director of Tecan Group AG from April 22, 2009 until April 2012. He graduated with Master of Science degree from Eidgenoessische Technische Hochschule Zueric (Swiss Federal Institute of Technology) in chemistry and holds a Ph.D. degree in Physical Chemistry from the same university. From 2011 to March 2018 he was |chief Executive Officer of Sonova Holding AG. From 2009 to 2011 he served as Chief Executive Officer of RUAG Holding AG. Previously, he held various management positions, including President &CEO and Member of the Board of Directors at Dionex Corporation (2002-2009), Member of the Group Executive Board, Executive Officer and Group Vice President at Mettler-Toledo International Inc, as well as President of Mettler-Toledo, Inc (1995-2000), Senior Member of the Regional Management Board, Executive Vice President of Landis & Gyr Europe AG at Landis & Gyr AG (now Siemens AG, 1992-1995), Senior Member of the Executive Board of Saurer Group Holding AG (1991-1992), Member of the Executive Board and Head of the Special Materials and Plastics Division at Huber + Suhner AG (1988-1991) and Member of the Special Products Division Management at Wild Leitz Heerbrugg AG (now Leica Geosystems, 1985-1988). He serves as Board Member of the Schweiter AG.

David Martyr

Dr. David R. Martyr has been Chief Executive Officer and Member of the Management Board of Tecan Group Ltd. since October 2012. He holds B.Sc. and doctorate in Engineering from University of Newcastle. From 1984 to 1988 he held sales and marketing management positions at Ferranti plc; from 1989 to 1998 he occupied variety of management and sales-related positions at Lumonics Inc., including Managing Director Europe; between 1998 and 2007 he held various senior management and professional positions at Leica Microsystems, including Executive Vice President Worldwide Sales and Marketing and Managing Director Europe. From 2009 to 2011 he was Group Executive and Vice President of Danaher Corporation, the shareholder of Leica Microsystems Group, overseeing the development of Danaher’s Life Sciences businesses; from 2007 to 2011 he served as Group President of Leica Microsystems Group with full responsibility for Leica Microsystems, Leica Biosystems and Invetech.

Heinrich Fischer

Mr. Heinrich Fischer has been Non-Executive Vice Chairman of the Board of Tecan Group Ltd. since December 31, 2007. He is also Chairman of the Audit Committee and Member of the Nomination and Governance Committee at the Company. He was appointed to the Board on April 19, 2007. He holds Master of Applied Physics and Electrical Engineering from Eidgenoessische Technische Hochschule Zuerich (ETH, Swiss Federal Institute of Technology) and a Master of Business Administration from Universitaet Zuerich. He spent four years in Research & Development in electronics (ETH Zurich, IBM). From 1980 to 1990, he was Director of Staff Technology and Executive Vice President at Balzers Division of Oerlikon-Buehrle Group. From 1991 to 1996, he was Executive Vice President, Corporate Development at Oerlikon-Buehrle Group. From 1994 to 2005, he was Cofounder and Chairman of ISE (Integrated System Engineering). From 1996 to 2007, he was a Delegated member of the board and Chief Executive Officer of Saurer Group. Since 2007 he has served at DiamondScull AG as owner and Chairman of the Board.

Rudolf Eugster

Dr. Rudolf Eugster has been Chief Financial Officer and Member of the Management Board at Tecan Group Ltd. since December 1, 2002. He was involved in strategic planning and controlling at Novartis from 1993 until 1994 and held several positions at Von Roll between 1994 and 2002, the last of which was Chief Financial Officer of Isola Composites, a joint venture between Von Roll and Isola AG. He has a degree in Chemistry, a Doctorate in Philosophy in Technical Science and a postgraduate degree in Business Administration, all from Eidgenoessische Technische Hochschule Zuerich (Swiss Federal Institute of Technology).

Ulrich Kanter

Mr. Ulrich Kanter has been Executive Vice President, Head of the Division Development and Operations and Member of the Management Board at Tecan Group Ltd. since July 2014. From 1995 to 2000 he was Vice President, Operations and Global Supply Chain Manager at AVL Medizintechnik (acquired by Roche Diagnostics in 2000); and from 2000 to 2014 he held diverse positions with increasing management responsibility at Roche Diagnostics, most recently as General Manager and Head of Research & Development in Graz, Austria. He is Mechanical Engineer (Berufsakademie Mannheim, Germany) and holds a Diploma in Business Administration (Verwaltungs- und Wirtschaftsakademie at the J.W. Goethe Universitaet Frankfurt am Main).

Andreas Wilhelm

Mr. Andreas Wilhelm has been Executive Vice President, General Counsel and Secretary of the Board of Directors, Member of the Management Board of Tecan Group Ltd. since 2012. Since 2004 he has been Head Legal Affairs and Secretary of the Board of Directors of the Company. Previously, in 1993 he served as Judicial Clerk at District Court of Nidau, from 1994 to 1995 as Legal Internship at Notter&Partner in Berne, from 1996 to 1999 attorney at- law at Gruninger Hunziker Roth Rechtsanwalte in Berne, from 2000 to 2004 attorney-at-law at Bar & Karrer in Zurich. He holds a Master of Law degree from Boston University and a Law degree from University of Bern.

Markus Schmid

Mr. Markus Schmid has been Executive Vice President, Head of Corporate Human Resources & Internal Communications and Member of the Management Board at Tecan Group Ltd. since 2011. Between 1990 and 1993 he acted as consultant for occupational pension funds at an insurance company. In years 1994-1998 he was teacher and instructor at various educational levels, and held various consulting positions. From 1998 to 2011 he acted as partner and operations manager at MANRES AG. He holds Masters degree in Psychology and Journalism from Freiburg University.

Klaus Lun

Dr. Klaus Lun has been Executive Vice President, Head of the Life Sciences Business Division, Member of the Management Board of Tecan Group Ltd. since February 2017. He was Executive Vice President, Head of Corporate Development and Member of the Management Board of Tecan Group Ltd. from June 2013. He held variety of positions at Amaxa GmbH, now part of the Lonza Group from 2002 to 2007, most recently as a Senior Project Manager, 2007 to 2011 Director Business Development at Leica Microsystems (Danaher Group); 2011 to 2013 Several management positions at Molecular Devices Inc. (Danaher Group), most recently as Vice President Drug Discovery and Bioresearch und Vice President Global Product Marketing. He holds a M.Sc. in Biology from the University of Tuebingen, Dr. rer. nat. in neurobiology (equiv. Ph.D.), from the University of Heidelberg and an MBA degree from the University of Mannheim.

Erik Norstrom

Mr. Erik Norstrom has been Executive Vice President, Head of Corporate Development, Member of the Management Board at Tecan Group Ltd. since December 2017. From 1999 to 2001 he served at Capex Analyst at F. Hoffmann-La Roche AG, Basel; from 2001 to 2008 he was Corporate Development Director at F. Hoffmann - La Roche AG, Basel; from 2008 to 2012 he acted as Head of M&A and alliances at Nobel Biocare AG, Zürich. From 2012 to 2015 he served as Head of Corporate Development and M&A Member of the Corporate Leadership Team at Nobel Biocare AG and from 2015 to 2017 he was Corporate Vice President strategic development and M&A Member of the Corporate Leadership team at Chr. Hansen a/s, Copenhagen, Denmark. He has Master of Science in Chemical Engineering from Chalmers University of Technology and Bachelor of Science in Business Administration from Goteborg University, School of Business, Economics and Law.

Achim von Leoprechting

Dr. Achim von Leoprechting has been Executive Vice President, Head of the Partnering Business Division, Member of the Management Board at Tecan Group Ltd. since October 2013. He held different positions in product management at Packard Bioscience, today part of PerkinElmer from 1999 to 2002; from 2002 to 2013 Several management positions and professional positions at PerkinElmer Inc., including Vice President and General Manager In Vitro Solutions and Vice President and General Manager Imaging and Detection Technologies as well as European Sales Director Molecular Medicine/Biodiscovery; most recently as Vice President and General Manager Europe, Middle East, Africa and India. He holds a Ph.D. in Biology from University of Freiburg, Germany.

Oliver Fetzer

Dr. Oliver S. Fetzer, Ph.D., has been Non-Executive Director at Tecan Group Ltd. since 2011. He serves as Member of the Compensation Committee at the Company. He graduated from the Carnegie Mellon University with a Masters of Business Administration degree and holds a Ph.D. title in Pharmaceutical Sciences from the Medical University of South Carolina, the United States. From 1993 to 2002 he worked for the Boston Consulting Group. Between 2000 and 2002 he served as Managing Director and Partner for that company. From 2002 to 2007 he held various management positions, including Senior Vice President, Corporate Development and Research and Development at Cubist Pharmaceuticals. From 2007 to 2008 he worked for Sabbatical and from 2009 to 2014 he was President and Chief Executive Officer, Member of the Board of Directors of Cerulean Pharma Inc. Since 2014 he has been Chief Executive Officer and Member of the Board of Synthetic Genomics.

Lars Holmqvist

Mr. Lars Holmqvist has been Non-Executive Director of Tecan Group Ltd. since April 2015. He is Member of the Audit Committee at the Company. From 2012 to 2014 he was President of Life Sciences and Diagnostics Group / Senior Vice President of Agilent of Agilent Technology, Inc. Prior to that, from 2009 he was President and CEO of Dako Denmark A/S. From 2004 to 2009 he held various positions, last position President and Executive Member of Applera Corp. at Applied Biostems, Inc. From 1998 till 2004 he held various positions, last position Vice President Vascular & Cardic Surgrey, Western Europe, Member of the European Management Committee and Global Vascular & Cardiac at MEDITRONICEUROPE SARL. Moreover, Mr. Holmqvist served at Boston Scientific Europe, Pharma Hospital Care, Becton Dickinson Nordic and Lederle Labs. Nordic. He graduated from INSEAD, Fontainebleu France and holds a degree in Business Administration from Mid Sweden University, Sweden.

Karen Huebscher

Dr. Karen Huebscher has been Non-Executive Director of Tecan Group Ltd. since April 2012. She is Member of the Audit Committee at the Company. Previously from 1995 to 1997 she was Research Scientist at Novartis and CIBA-Geigy, from 1997 to 2000 served as Investor Relations Manager at Novartis and from 2000 to 2005 she served as Global Head of Investor Relations. From 2006 to 2009 she was Global Head Business Development/Mergers and Acquisitions and member of the Executive Committee and Innovation Board at Novartis Vaccines & Diagnostics, USA. From 2009 to 2011 she was Head Public Health and Market Access Europe, Member of the European Commercial Operations Leadership Team and Site Head at Novartis Vaccines & Diagnostics, Basel. Since 2012 she has been Founder and Managing Director of Fibula Medical AG and since 2014 she has served as CEO of Solvias AG. She holds a Doctorate in Philosophy in Natural Sciences and a Masters degree in Animal Sciences from ETH Zurich. She also holds a Masters of Business Administration from IMD Lausanne.

Christa Kreuzburg

Dr. Christa Kreuzburg has been Non-Executive Director at Tecan Group Ltd. since April 2013. She is Chairwoman of the Compensation Committee and Member of the Nomination and Governance Committee at the Company. She was from 1990 to 1994 Laboratory Head, Central Research at Bayer AG, Germany; from 1994 to 1996 Departmental Head, Central Research at Bayer AG, Germany; from1997 to 1999 Strategy Consultant, Corporate Strategic Planning at Bayer AG, Germany; from 2000 to 2002 Head of Corporate Strategic Planning, in addition from 2001, heading the restructuring project of division Pharmaceuticals after the withdrawal of Lipobay at Bayer AG, Germany; from 2002 to 2005 Head of Pharma Japan (from 2004)/Europe/ MERA and member of the Pharma Management Committee at Bayer HealthCare, Germany; from 2006 to 2007 Head of Pharma Primary Care / International Operations and member of the Pharma Management Committee at Bayer HealthCare, Germany; from 2007 to 2008 Head of Bayer Schering Pharma Europe/ Canada and member of the Executive Committee. Integration of Bayer and Schering in the region at Bayer HealthCare, Germany. Since 2009 she manager consulting projects for small and mid-size Healthcare companies. She holds a Diploma and Ph.D. in Physical Chemistry from Universitaet Duisburg.

Daniel Marshak

Dr. Daniel R. (Dan) Marshak, Ph.D., has been Non-Executive Director at Tecan Group Ltd. since 2018. He is Member of the Compensation Committee at the Company. From 1986 to 1995 he served at Cold Spring Harbor Laboratory as Senior Staff Investigator. From 1994 to 2000 he worked for Osiris Therapeutics, Inc. as Senior Vice President and Chief Scientific Officer and Senior Vice President, Research and Development and Chief Technology Officer. Moreover, between 2000 and 2006 he served at Cambrex Corporation as Vice President and Chief Technology Officer, Biotechnology and Vice President Research and Development, Biosciences. From 2006 to 2014 he worked for PerkinElmer, Inc., and in his last role as Senior Vice President and Chief Scientific Officer, he was responsible for all science and technology as well as research and development activities and also led several acquisitions during that time. Additional positions at PerkinElmer included President, Emerging Diagnostics, Waltham, USA and Shanghai, China and President, Greater China, Shanghai, China. Since 2014 he has provided consultancy for various companies in the Life Sciences, BioPharmaceutical, and Diagnostics industry. He holds a Ph.D. in Biochemistry and Cell Biology from The Rockefeller University, and Bachelor in Biochemical Sciences from Harvard University.

Martin Braendle